Evidence map›Paper›PMID 35347100›Full record

ArticleClinical and translational gastroenterology2022

Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies.

Brigid S Boland, Benjamin Goodwin, Zeli Zhang, Nathaniel Bloom, Yu Kato, Jennifer Neill, Helen Le, Tiffani Tysl, Angelina E Collins, Parambir S Dulai and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Brigid S BolandDivision of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Benjamin GoodwinCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Zeli ZhangCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Nathaniel BloomCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Yu KatoCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Jennifer NeillDivision of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Helen LeDivision of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Tiffani TyslDivision of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Angelina E CollinsDivision of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Parambir S DulaiDivision of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Siddharth SinghDivision of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Nghia H NguyenDivision of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Alba GrifoniCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Daniela WeiskopfCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
John T ChangDivision of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Jennifer M DanCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
University of California, San Diego · USLa Jolla Institute for Immunology · US

Funding

T follicular helper (Tfh) CD4+ T cell, germinal center, and antibody response dysfunction in human recurrent tonsillitisU19AI142742 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Alessandro Sette · 2019 to 2026
$32.8M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, Bernd G. Schnabl · 2019 to 2026
$10.8M
San Diego Biomedical Informatics Education & Research (SABER)T15LM011271 · NLM · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHAMIM NEMATI · 2012 to 2026
$9.7M
UC San Diego RAPID Faculty Development Program in Infectious DiseasesR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADRIANA H TREMOULET, Joann Trejo · 2020 to 2026
$2.5M
CD4 T cell, germinal center, and antibody response defects in recurrent tonsillitisR01AI135193 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROTTY, SHANE P · 2018 to 2022
$2.3M
The Immunology of Recurrent Group A Streptococcus TonsillitisK08AI135078 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAN, JENNIFER MARIE · 2018 to 2022
$972k
USING SINGLE-CELL RNA AND PROTEIN APPROACHES TO ELUCIDATE MOLECULAR DETERMINANTSAND PREDICTORS OF INFLAMMATORY BOWEL DISEASESK23DK123406 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOLAND, BRIGID S · 2020 to 2022
$720k
NIAID NIH HHS K08 AI135078NIAID NIH HHS R01 AI135193NIAID NIH HHS R25 AI147376NIAID NIH HHS U19 AI142742NIDDK NIH HHS K23 DK123406NIDDK NIH HHS P30 DK120515NLM NIH HHS T15 LM011271
6 · The paper itself

Abstract

Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.

Indexed as

COVID-19Inflammatory Bowel DiseasesChronic DiseaseCOVID-19 VaccinesHumansInfliximabSARS-CoV-2COVID-19 VaccinesInfliximab

Identifiers

PMID35347100
PMCPMC9038482
OpenAlexW4220826708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.